Recombinant a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) for acute and prophylactic treatment of congenital thrombotic thrombocytopenic purpura in pregnancy
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.05.006 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Taeer Avnon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel; School of Medicine…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, ADAMTS13 Protein, Pregnancy Complications, Hematologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Thrombotic thrombocytopenic purpura (TTP) is a disorder of the absence or severe depletion of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) protease, which cleaves von Willebrand factor multimers. In its absence, exposed platelet binding sites on large von Willebrand factor multimers bind and aggregate platelets, causing microangiopathic hemolytic anemia and thrombosis. The rare congenital form of TTP (cTTP) is caused by mutations in the ADAMTS-13 gene. Pregnant cTTP patients are at very high risk of developing complications. Current recommendations for pregnant cTTP patients are prophylactic fresh-frozen plasma infusions; however, efficacy varies among patients. Recombinant ADAMTS-13 (rADAMTS-13) is a novel alternative to plasma infusions, recently reported to be effective and safe for treating nonpregnant cTTP patients. Few studies have attempted to treat pregnant cTTP patients with rADAMTS-13. We present a case of successful treatment with rADAMTS-13 for acute TTP exacerbation and maintenance during pregnancy in a cTTP patient with a history of pregnancy complications and insufficient response to plasma infusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel; School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer…
- School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Thrombosis and Hemostasis Unit, Hematology Institute, Soroka University Medical Center, Faculty of Health Sciences,…
- School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Hematology Institute, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Ne…
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Avnon, T., Rabinovich, A., Pikovsky, O., Pariente, G., & Erez, O. (2025). Recombinant a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) for acute and prophylactic treatment of congenital thrombotic thrombocytopenic purpura in pregnancy. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.05.006
Vancouver
Avnon T, Rabinovich A, Pikovsky O, Pariente G, Erez O. Recombinant a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) for acute and prophylactic treatment of congenital thrombotic thrombocytopenic purpura in pregnancy. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.05.006
BibTeX
@article{Avnon2025,
author = {Avnon, Taeer and Rabinovich, Anat and Pikovsky, Oleg and Pariente, Gali and Erez, Offer},
title = {Recombinant a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) for acute and prophylactic treatment of congenital thrombotic thrombocytopenic purpura in pregnancy},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.05.006}
}
EUVIMED